2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Imaging, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Antibody Therapy, Transfusion, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Checkpoint Inhibitor, Immunotherapy, Infusion, Monoclonal Antibody Therapy, Non-Biological Therapies, Chemotherapy, Workforce, Adverse Events, Biological Processes, Metabolism, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality of Care, Value, Diseases, Bleeding and Clotting, Thromboembolism, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, CLL, Hodgkin Lymphoma, Non-Hodgkin Lymphoma, B Cell Lymphoma, T Cell Lymphoma, Indolent Lymphoma, Aggressive Lymphoma, Research, AML, APL, Translational Research, MDS, MPN, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

4501 Health outcomes in socially vulnerable pediatric patients after hematopoietic cell transplantation

Emmanuel Aryee, MD, Yushan Yang2, Ruta Brazauskas, PhD3, Larisa Broglie, MD, MS4
1 Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
2 Medical College of Wisconsin, Milwaukee, Wisconsin, United States
3 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Biostatistics, Data Science Institute, Medical College of Wisconsin, Milwaukee, Wisconsin, United States
4 CIBMTR® (Center for International Blood and Marrow Transplant Research), Medical College of Wisconsin, Milwaukee, Wisconsin, United States, Division of Pediatric Hematology/Oncology/Blood and Marrow Transplant, Department of Pediatrics, Medical College of Wisconsin, Milwaukee, Wisconsin, United States

Background:

Socioeconomic and demographic disparities can profoundly impact health outcomes. The Minority Health Social Vulnerability Index (MHSVI) is a comprehensive tool used to evaluate the burden of social vulnerability on communities. However, its specific impact on pediatric patients undergoing hematopoietic cell transplantation (HCT) remains poorly understood.

Objective:

To evaluate the association between social vulnerability measured by MHSVI and long-term clinical outcomes after HCT including overall survival (OS), disease-free survival (DFS), relapse risk, and treatment-related mortality (TRM) in a pediatric and young adult cohort.

Methods: We analyzed data from a CIBMTR publicly available dataset (P5628) of patients < 39yo who received HCT between 2008 and 2017. Demographic, clinical, and transplant characteristics were described; MHSVI was categorized for each patient based on reported ZIP code. OS and DFS probabilities were calculated using Kaplan-Meier curves.  Cumulative incidence curves were used to summarize the risk of relapse and TRM over time. Multivariate Cox proportional hazards models were utilized to determine association of MHSVI with OS, DFS, relapse, and TRM, after adjusting for patient, disease, and treatment characteristics.

Results: Unadjusted analysis demonstrated a statistically significant difference in OS and DFS across MHSVI categories  (p=0.02). However, in adjusted multivariate Cox models, MHSVI category was not a statistically significant predictor for any post-transplant outcome: OS (global p=0.487), DFS (global p=0.364), relapse risk (global p=0.337), and TRM (global p=0.668).

Clinical characteristics and specific sociodemographic factors emerged as powerful independent predictors of inferior outcomes. Public insurance was independently associated with an increased risk of death (HR=1.22 [95%CI 1.12 - 1.33]) and TRM (HR=1.25 [95%CI 1.10 - 1.42]) compared to private insurance. African American race was also an independent predictor of worse outcomes, including a higher risk of death (HR=1.35 [95%CI 1.19 - 1.52]) and TRM (HR=1.53 [95%CI 1.29 -1.81]) compared to Caucasian patients. Additionally, patients transplanted in the later cohort (2013–2017) experienced significantly superior outcomes compared to the 2008–2012 cohort, with a 31% reduction in mortality risk (HR=0.69 [0.63 - 0.76]) and a 35% reduction in TRM (HR=0.65 [0.57- 0.74]).

Conclusions: While composite community-level social vulnerability via MHSVI does not independently predict pediatric HCT outcomes once adjusted for clinical variables, individual-level factors such as public insurance and African American race remain significant predictors of worse survival and treatment safety outcomes. Furthermore, pre-transplant clinical comorbidities and performance status are significantly associated with post-transplant success. Targeted interventions focusing on high-risk clinical cohorts and specific vulnerable demographic groups are warranted to further close the equity gap in pediatric HCT.

Emmanuel Aryee, MD: No relevant conflicts of interest to declare.